الصفحة 1
الصفحة 1
Infections à papillomavirus : État des connaissances, pratiques et prévention vaccinale = Human papillomavirus infections : Current knowledge, practices and vaccination prevention
The impact of papillomavirus (HPV) infection is considerable. More than one in two women has been exposed to HPV in her lifetime and around 10% will develop a chronic infection. Of these, 20% will develop cervical cancer in the absence or failure of screening. In France, high-risk HPV infection causes 80,000 precancerous lesions, 3,400 cervical cancers and the death of 1,000 women every year. Smear screening performed at a regular rate and according to quality standards has resulted in a significant decrease in incidence and mortality over the past 20 years. However, despite this considerable success, the so-called preventable disease has not been eradicated; testing is a complex process that only benefits part of the population while those who benefit endure its weaknesses. Optimization of screening and treatment is now made possible by the use of innovative techniques including the smear in liquid suspension, the HPV test, and soon viral genotyping and molecular markers guaranteeing maximum protection. Because cervical cancer is the result of chronic HPV infection, we already have the extraordinary chance to prevent it with a prophylactic vaccine. This progress will have a major impact on our practices as it happens in a poorly prepared medico-sociological environment. This resolutely practical and educational book provides an overview of knowledge and perspectives on HPV infection and its associated pathologies while deciphering the new challenges and practices in the vaccine era.
Les thérapies ciblées = Targeted therapies
We are at the start of the development of new therapeutic classes, directed against new molecular targets (EGFR, VEGF, IGFR, Rank, etc.) Several diseases such as kidney, colon or breast cancer, GIST, have a natural history now modified thanks to these therapies. This practical book takes stock of the current use of these molecules.
Le dépistage du cancer du col de lutérus = Cervical cancer screening
Each year, cervical cancer kills approximately 1,000 people in France, making it the fifth leading cause of cancer death and the eighth most common cancer among women. While eradicating cervical cancer is not possible, a national screening campaign should significantly reduce its incidence. This campaign should be based, in particular, on the systematic use of Pap smears. Conventional Pap smears have already reduced the number of invasive cancers by more than 50%. Improving them requires optimizing their sensitivity. This book details the natural history of cervical cancer, its incidence and mortality, and the various aspects of screening: general principles, the French screening program, the different types of Pap smears, the role and contribution of the HPV test, the management of abnormal Pap smears, the role of colposcopy, and the follow-up of treated women. It is intended for all those involved in this screening : specialist interns and gynecologists, pathologists and biologists, public health physicians, but also general practitioners whose role in screening is privileged since they are at the forefront of medical demand.
